Tianjin Hematonosis Hospital
Welcome,         Profile    Billing    Logout  
 11 Trials 
12 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Junyuan, Qi
NCT06558513: To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors

Recruiting
1/2
176
RoW
XNW5004 tablets
Evopoint Biosciences Inc., Shanghai Dingyue Biotechnology Co., LTD, Beijing Jiyingjia Medical Laboratory Co.,Ltd., Shanghai Jinghan Biological Technology Co., Ltd.
Advanced Tumor, Lymphoma
12/24
12/24
Yi, Shuhua
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/25
08/26
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma

Recruiting
3
356
RoW
Orelabrutinib and R-CHOP, R-CHOP
Beijing InnoCare Pharma Tech Co., Ltd.
Treatment-naїve Mantle Cell Lymphoma
12/24
12/27
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma

Active, not recruiting
2
62
RoW
Rocbrutinib, NWP-775, LP-168
Guangzhou Lupeng Pharmaceutical Company LTD.
Mantle Cell Lymphoma (MCL)
12/24
12/25
NCT04808570: A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Terminated
1/2
23
RoW
TQ-B3525 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
11/23
11/23
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting
1/2
123
RoW
APG-2575, Rituximab, Ibrutinib
Ascentage Pharma Group Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
12/24
12/25
NCT05944978: A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Recruiting
1/2
40
RoW
GNC-035
Sichuan Baili Pharmaceutical Co., Ltd.
Relapsed/Refractory Chronic Lymphocytic Leukemia
08/25
08/25
ICP-CL-01201, NCT05728658: The Study of ICP-248 in Patients with Mature B-cell Malignancies

Recruiting
1
191
RoW
ICP-248, ICP-248+Orelabrutinib
Beijing InnoCare Pharma Tech Co., Ltd.
Hematological Malignancies
08/25
10/26
MAPLE-1, NCT04260217: APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia

Completed
1
46
US, RoW
APG2575 400 mg, APG2575 600 mg, APG2575 800 mg
Ascentage Pharma Group Inc.
Waldenstrom Macroglobulinemia
02/24
02/24

Download Options